Michael Okunewitch
Stock Analyst at Maxim Group
(0.69)
# 4,140
Out of 4,655 analysts
396
Total ratings
38.1%
Success rate
-1.5%
Average return
Main Sectors:
Stocks Rated by Michael Okunewitch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VNRX VolitionRx | Maintained: Buy | n/a | $0.50 | - | 4 | Aug 18, 2026 | |
| MDWD MediWound | Reiterated: Buy | $30 | $13.39 | +124.05% | 28 | Aug 14, 2026 | |
| LGVN Longeveron | Maintained: Hold | n/a | $0.82 | - | 25 | Aug 14, 2026 | |
| BLTE Belite Bio | Maintained: Buy | $200 | $163.21 | +22.54% | 14 | Aug 14, 2026 | |
| DFTX Definium Therapeutics | Rated: Buy | $50 → $55 | $45.26 | +21.52% | 16 | Aug 13, 2026 | |
| ACRV Acrivon Therapeutics | Maintained: Buy | $7 | $2.05 | +241.46% | 13 | Aug 13, 2026 | |
| LCTX Lineage Cell Therapeutics | Maintained: Buy | $3 | $1.06 | +183.02% | 16 | Aug 11, 2026 | |
| KPRX Kiora Pharmaceuticals | Rated: Buy | $12 | $2.59 | +363.32% | 32 | Aug 10, 2026 | |
| OCGN Ocugen | Rated: Buy | $8 | $1.38 | +481.82% | 23 | Aug 10, 2026 | |
| CTOR Citius Oncology | Rated: Buy | $4 | $0.74 | +440.54% | 13 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $13.72 | +45.77% | 12 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $165 | $138.92 | +18.77% | 24 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $7.24 | - | 20 | Jul 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $0.7959 | +528.22% | 15 | Jul 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $1.92 | +161.10% | 13 | Jul 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $2.52 | +98.41% | 24 | Jun 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | - | - | 2 | May 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $3.13 | +219.49% | 3 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.02 | - | 8 | May 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $10 → $12 | $1.68 | +614.29% | 2 | Apr 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $1 | $0.22 | +354.55% | 23 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 | $2.67 | +461.80% | 7 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.47 | - | 6 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $0.562 | - | 28 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $6.9 | $1.58 | +336.71% | 6 | Sep 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $4.57 | n/a | 1 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $10.32 | n/a | 11 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.20999999 | n/a | 3 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $0.6422 | n/a | 4 | May 9, 2023 |
VolitionRx
Aug 18, 2026
Maintained: Buy
Price Target: n/a
Current: $0.50
Upside: -
MediWound
Aug 14, 2026
Reiterated: Buy
Price Target: $30
Current: $13.39
Upside: +124.05%
Longeveron
Aug 14, 2026
Maintained: Hold
Price Target: n/a
Current: $0.82
Upside: -
Belite Bio
Aug 14, 2026
Maintained: Buy
Price Target: $200
Current: $163.21
Upside: +22.54%
Definium Therapeutics
Aug 13, 2026
Rated: Buy
Price Target: $50 → $55
Current: $45.26
Upside: +21.52%
Acrivon Therapeutics
Aug 13, 2026
Maintained: Buy
Price Target: $7
Current: $2.05
Upside: +241.46%
Lineage Cell Therapeutics
Aug 11, 2026
Maintained: Buy
Price Target: $3
Current: $1.06
Upside: +183.02%
Kiora Pharmaceuticals
Aug 10, 2026
Rated: Buy
Price Target: $12
Current: $2.59
Upside: +363.32%
Ocugen
Aug 10, 2026
Rated: Buy
Price Target: $8
Current: $1.38
Upside: +481.82%
Citius Oncology
Aug 10, 2026
Rated: Buy
Price Target: $4
Current: $0.74
Upside: +440.54%
Aug 7, 2026
Reiterated: Buy
Price Target: $20
Current: $13.72
Upside: +45.77%
Aug 6, 2026
Reiterated: Buy
Price Target: $165
Current: $138.92
Upside: +18.77%
Jul 17, 2026
Downgraded: Hold
Price Target: n/a
Current: $7.24
Upside: -
Jul 15, 2026
Maintained: Buy
Price Target: $5
Current: $0.7959
Upside: +528.22%
Jul 13, 2026
Maintained: Buy
Price Target: $5
Current: $1.92
Upside: +161.10%
Jun 24, 2026
Maintained: Buy
Price Target: $5
Current: $2.52
Upside: +98.41%
May 21, 2026
Maintained: Buy
Price Target: $5
Current: -
Upside: -
May 7, 2026
Maintained: Buy
Price Target: $10
Current: $3.13
Upside: +219.49%
May 4, 2026
Downgraded: Hold
Price Target: n/a
Current: $1.02
Upside: -
Apr 9, 2026
Rated: Buy
Price Target: $10 → $12
Current: $1.68
Upside: +614.29%
Apr 8, 2026
Maintained: Buy
Price Target: $1
Current: $0.22
Upside: +354.55%
Mar 25, 2026
Maintained: Buy
Price Target: $15
Current: $2.67
Upside: +461.80%
Mar 6, 2026
Downgraded: Hold
Price Target: n/a
Current: $1.47
Upside: -
Sep 23, 2025
Maintained: Hold
Price Target: n/a
Current: $0.562
Upside: -
Sep 13, 2025
Maintained: Hold
Price Target: $6.9
Current: $1.58
Upside: +336.71%
Mar 3, 2025
Maintained: Buy
Price Target: $12
Current: $4.57
Upside: n/a
Sep 13, 2024
Maintained: Buy
Price Target: $12
Current: $10.32
Upside: n/a
Dec 19, 2023
Downgraded: Hold
Price Target: n/a
Current: $0.20999999
Upside: n/a
May 9, 2023
Maintained: Buy
Price Target: n/a
Current: $0.6422
Upside: n/a